Arrowhead Pharmaceuticals
Arrowhead develops RNAi therapeutics using its TRiM platform, which combines RNA triggers, targeting ligands, linkers, and chemical modifications. Liver and extrahepatic programs must be assessed by candidate and indication.
Corporate information
- Company entity
- Arrowhead Pharmaceuticals
- Headquarters / principal office
- Pasadena, CaliforniaSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 1989 (legal predecessor); Delaware reincorporation 2000 ↗
- Ownership / capital status
- Publicly tradedNasdaq Global Select Market; ARWR ↗
- Official corporate reference
- https://arrowheadpharma.com/en-us/science-and-innovation ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Arrowhead develops RNAi therapeutics using its TRiM platform, which combines RNA triggers, targeting ligands, linkers, and chemical modifications. Liver and extrahepatic programs must be assessed by candidate and indication.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Arrowhead Pharmaceuticals — official disclosure
- Arrowhead Pharmaceuticals — official company page
- Arrowhead investor FAQs — Nasdaq ARWR
- Company-managed LinkedIn profile — self-reported location